Abstract 320P
Background
Ovarian cancer is 3rd most common malignancy in Indian women and 8th common cause of cancer related death in India. The aim for this study was to evaluate clinicopathological factors, patterns of treatment, progression free survival (PFS) and overall survival (OS) in Indian patients with advanced ovarian cancer.
Methods
This is a retrospective analysis of patients with stage III-IV ovarian cancer treated at HCG Cancer Center, Ahmedabad from June 2018- March 2023. Patients were identified using the institutional tumor registry and medical records and data was collected.
Results
Out of total 94 patients identified; 79 patients were eligible for further analysis. Median age was 55 years (range 29 to 76 years). 62 (78%) patients had stage III (IIIA-5,IIIB-3, IIIc-44) & 17 (22%) had stage IV (IVA-10, IVB-7). Most common histology was high grade serous carcinoma in 76 (96%) patients. Majority of patients received neoadjuvant chemotherapy followed by interim cytoreductive surgery (CRS), [61 patients (78%)] whereas 18 patients (22 %) underwent upfront surgery. Median duration of neoadjuvant chemotherapy was 3 months. 21 (26.57%) patients were treated with hyperthermic intraperitoneal chemotherapy (HIPEC). 60 patients (76%) received maintenance therapy [43 patients bevacizumab, 10 patients PARP (poly ADP ribose polymerase) inhibitor and 6 patients received both]. 33 patients (41%) developed recurrence among which 32 received further chemotherapy. In recurrent setting, patients received a median 3 lines of systemic therapy (range 0-5). Genetic testing was offered to all patients at the time of diagnosis, but only 36 (45%) patients opted for it. BRCA1 mutation was detected in 8 patients (22.2%), BRCA2 mutation in 4 (11%). Median follow up was 17 months. Median PFS was 20 months with 95% CI (16-22) & Median OS was not reached, 5-year OS was 32.1%.
Conclusions
Median PFS and OS in advanced ovarian cancer at our institute is comparable to global standards. With the availability of biosimilars and genetic testing, more patients are able to access maintenance therapies. Hopefully more patients can access standard of care therapies which will help close the gap between less developed and developed countries in terms of long term outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract